CLN5 Gene Therapy Trial to Start Early Next Year in Rochester

CLN5 Gene Therapy Trial to Start Early Next Year in Rochester

312336

CLN5 Gene Therapy Trial to Start Early Next Year in Rochester

Enrollment in a clinical trial testing NGN-101 — an experimental gene therapy for CLN5, a type of late-infantile Batten disease — is expected to start early next year at the University of Rochester Medical Center (URMC). “This trial will move research forward in developing a potentially disease-modifying treatment for CLN5 disease, providing hope to individuals and families where currently none exists,” Jonathan Mink, MD, PhD, a professor of pediatric neurology and chief of child neurology…

You must be logged in to read/download the full post.